Ocular Releases Phase 3 Data for Wet AMD Candidate Axpaxli episode artwork

EPISODE · Feb 18, 2026 · 6 MIN

Ocular Releases Phase 3 Data for Wet AMD Candidate Axpaxli

from Eyewire News: The Podcast · host Eyewire News

Ocular Therapeutix releases its long-awaited SOL-1 phase 3 data for wet AMD drug candidate Axpaxli; Nordic Pharma expands the availability of its novel dry eye therapy Lacrifill; and Alcon launches the only multifocal toric contact lens featuring Water Gradient Technology. Learn more about your ad choices. Visit megaphone.fm/adchoices

NOW PLAYING

Ocular Releases Phase 3 Data for Wet AMD Candidate Axpaxli

0:00 6:02

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Eyewire News: The Podcast?

This episode is 6 minutes long.

When was this Eyewire News: The Podcast episode published?

This episode was published on February 18, 2026.

What is this episode about?

Ocular Therapeutix releases its long-awaited SOL-1 phase 3 data for wet AMD drug candidate Axpaxli; Nordic Pharma expands the availability of its novel dry eye therapy Lacrifill; and Alcon launches the only multifocal toric contact lens featuring...

Can I download this Eyewire News: The Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!